United States securities and exchange commission logo





                            April 22, 2022

       David J. Arthur
       Chief Executive Officer
       Salarius Pharmaceuticals, Inc.
       2450 Holcombe Blvd., Suite X
       Houston, TX 77021

                                                        Re: Salarius
Pharmaceuticals, Inc.
                                                            Form 10-K for the
Fiscal Year Ended December 31, 2021
                                                            Filed March 25,
2022
                                                            File No. 001-36812

       Dear Mr. Arthur:

               We have limited our review of your filing to the financial
statements and related
       disclosures and have the following comment. In our comment, we may ask
you to provide us
       with information so we may better understand your disclosure.

              Please respond to the comment within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comment applies to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to the comment, we may have additional comments.

       Form 10-K for the Fiscal Year Ended December 31, 2021

       Item 7. Management's Discussion and Analysis of Financial Condition and
Results of Operations
       Overview
       Research and Development Expenses, page 56

   1.                                                   We note the significant
increase in your research and development expenses in fiscal 2021
                                                        and that you have
multiple programs/products in varying stages of development and
                                                        clinical testing.
Please revise future filings to provide more details about your research
                                                        and development
expenses for each period presented, including but not limited to by
                                                        product/program as well
as by the nature of the expenses. To the extent that you do not
                                                        track expenses by
product candidate, please disclose as such. In addition, disclose the
                                                        specific reasons for
significant changes in research and development expenses each
                                                        period.
 David J. Arthur
Salarius Pharmaceuticals, Inc.
April 22, 2022
Page 2

       In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

      You may contact Christie Wong, Staff Accountant, at (202) 551-3684 or
Brian Cascio,
Accounting Branch Chief, at (202) 551-3676 with any questions.



FirstName LastNameDavid J. Arthur                         Sincerely,
Comapany NameSalarius Pharmaceuticals, Inc.
                                                          Division of
Corporation Finance
April 22, 2022 Page 2                                     Office of Life
Sciences
FirstName LastName